Cara Therapeutics Halts Trials for Itch Medication Difelikefalin
Company Announcements

Cara Therapeutics Halts Trials for Itch Medication Difelikefalin

Cara Therapeutics (CARA) has provided an update.

Cara Therapeutics, Inc. recently announced that their oral medication difelikefalin did not show significant benefits in treating severe itching associated with notalgia paresthetica compared to a placebo. Consequently, the company has decided to halt the clinical trials for this program. This news is notable for investors as it may impact the company’s future prospects and stock performance.

For detailed information about CARA stock, go to TipRanks’ Stock Analysis page.

Related Articles
Catie PowersCARA Earnings this Week: How Will it Perform?
Brian AndersonCARA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
TheFlyCara Therapeutics announces exploration of strategic alternatives
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App